In a study of men with bone metastases from metastatic castration-resistant prostate cancer, black men had no significantly greater risk of skeletal-related events than nonblack men.
Olaparib prolonged progression-free survival compared with abiraterone or enzalutamide in a phase 3 trial of men with metastatic castration-resistant prostate cancer who had certain DNA repair mutations and whose disease was progressing while receiving novel hormonal therapy.
Hospital stay was 1 day shorter for men undergoing robot-assisted laparoscopic prostatectomy with single-port access, and they reported less pain.
In a study of SEER registry patients with renal cell carcinoma, variant histology subtypes were associated with higher cancer-specific mortality than grade 4 clear-cell carcinoma.
A study of patients aged 70 or younger with high-risk prostate cancer found that black and Hispanic race was associated with a greater likelihood of receiving nondefinitive treatment, with patients experiencing poor outcomes as a result.
In a study, patients who had upper tract urothelial carcinoma with multifocal tumors had a 40% higher risk for urinary bladder recurrence than those with single tumors.
In a study, 8.8% of clinically relevant prostate cancers detected by systematic biopsy were missed by MRI-targeted biopsy.
Less intensive PSA screening in men with low PSA levels can substantially reduce unnecessary testing, according to investigators.
In a study, patients with upper tract urothelial carcinoma and pathologic vascular invasion who received adjuvant chemotherapy had significantly longer overall survival than those who did not receive adjuvant chemotherapy.
Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
